Drug Profile
Oleylphosphocholine
Alternative Names: D-121; OIPCLatest Information Update: 14 Nov 2023
Price :
$50
*
At a glance
- Originator Max Planck Innovation
- Developer Oblita Therapeutics
- Class Antiparasitics; Phospholipids; Quaternary ammonium compounds
- Mechanism of Action Cell division inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chagas disease; Cryptosporidiosis; Leishmaniasis; Mycoses
Most Recent Events
- 14 Nov 2023 Oleylphosphocholine is still in phase I trials for Mycoses, Leishmaniasis, Cryptosporidiosis and Chagas-disease in Belgium (PO) (Oblita Therapeutics pipeline, November 2023)
- 21 Jun 2023 Phase-I clinical trials in Leishmaniasis in Germany (PO) (NCT06124144)
- 28 Mar 2019 No recent reports of development identified for phase-I development in Chagas-disease in Belgium (PO)